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DOI 10.1016/j.ccr.2011.02.008SUMMARYTo identify oncogenic pathways in T cell acute lymphoblastic leukemia (T-ALL), we combined expression
profiling of 117 pediatric patient samples and detailed molecular-cytogenetic analyses including the Chromo-
someConformation Capture on Chip (4C)method. Two T-ALL subtypeswere identified that lacked rearrange-
ments of known oncogenes. One subtype associated with cortical arrest, expression of cell cycle genes, and
ectopicNKX2-1 orNKX2-2 expression for which rearrangements were identified. The second subtype associ-
atedwith immature T cell development and high expressionof theMEF2C transcription factor as consequence
of rearrangements of MEF2C, transcription factors that target MEF2C, or MEF2C-associated cofactors. We
propose NKX2-1, NKX2-2, andMEF2C as T-ALL oncogenes that are activated by various rearrangements.INTRODUCTION
T-lineage acute lymphoblastic leukemia (T-ALL) is a malignancy
of thymocytes. T-ALL represents about 15% of pediatric ALLSignificance
For 40% of pediatric T-ALL cases, underlying oncogenic rea
profiling and molecular-cytogenetic techniques, we revealed t
and representing20% of pediatric T-ALL cases. One subtype
cases ectopically expressed NKX2-1/NKX2-2 for which five r
second subtype was associated with high MEF2C expression
or transcription factors and transcription cofactors that directl
sion of NKX2-1 or MEF2C was able to transform cells and int
NKX2-2, and MEF2C are oncogenes in leukemia.
484 Cancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc.cases but has an inferior outcome compared to B-ALL because
approximately 30% of T-ALL cases relapse during therapy or
within the first 2 years following treatment and eventually die
(Pieters and Carroll, 2008; Pui and Evans, 2006). T-ALL is mostlyrrangements remain unresolved. By combined expression
wo T-ALL entities lacking known oncogenic rearrangements
associated with cortical thymocytic arrest, and ten out of 12
earrangement variants were identified in seven cases. The
(11 out of 12 cases), and rearrangements involving MEF2C
y targetMEF2C were identified in six cases. Ectopic expres-
erfered with T cell differentiation. We propose that NKX2-1,
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NKX2-1 and MEF2C as Potential Oncogenes in T-ALLcharacterized by genetic abnormalities that are crucial for T cell
pathogenesis (Van Vlierberghe et al., 2008a). Various genetic re-
arrangements in T-ALL occur in amutually exclusive pattern (Van
Vlierberghe et al., 2008a) in contrast to frequent CDKN2A/ARF
deletions (Hebert et al., 1994) or NOTCH1-activating mutations
(Weng et al., 2004). These mutually exclusive rearrangements
are considered as driving chromosomal abnormalities that affect
the TAL1, LMO2, TLX1, TLX3, MYB, or HOXA oncogenes (Van
Vlierberghe et al., 2008a). Based on gene expression data (Fer-
rando et al., 2002; Soulier et al., 2005; Van Vlierberghe et al.,
2008b), these oncogenes have been associated with distinct
T-ALL subgroups denoted as the TAL/LMO, TLX1, TLX3, and
the HOXA subgroups. Initial profiling data also pointed to the
existence of an additional immature T-ALL subgroup (Soulier
et al., 2005). This entity probably corresponds to the LYL1
T-ALL subgroup as previously defined (Ferrando et al., 2002)
and to the recently described immature T-ALL subset that is
characterized by an early T cell precursor (ETP) profile and infe-
rior outcome (Coustan-Smith et al., 2009). For approximately
40% of all patients with T-ALL, including the immature T-ALL
entity, the driving chromosomal aberrations have thus far re-
mained elusive.
RESULTS
Cluster Analyses Predict T-ALL Genetic Subgroups
To identify driving oncogenic mechanisms in T-ALL, we
performed unsupervised hierarchical cluster analyses based
on microarray expression data of 117 diagnostic pediatric
T-ALL samples and seven normal bone marrow controls. A total
of 77 T-ALL samples was characterized by oncogenic rearrange-
ments, including TAL1 (n = 24), TAL2 (n = 1), LMO1 (n = 1), LMO1/
TAL2 (n = 1), LMO2 (n = 9), TLX3 (n = 22), TLX1 (n = 7), HOXA-
activating rearrangements (including CALM-AF10, Inv(7)
(p15q34), SET-NUP214; n = 10), or MYB translocations (n = 2).
No such abnormalities were identified in the remaining 40
T-ALL patient samples. Four robust T-ALL clusters were
observed in unsupervised cluster analysis, regardless of the
number of genes included or the data normalization methods
chosen (Figure 1A; see Figure S1 and Tables S1–S3 available
online). The association with clinical and molecular-cytogenetic
data, immunophenotypic markers, and expression of TAL1 and
LYL1 for these four subgroups is given in Table 1 and Figure 1A.
Two clusters represented established T-ALL genetic subgroups
(Ferrando et al., 2002; Soulier et al., 2005; Van Vlierberghe et al.,
2008b), corresponding to abnormalities of TAL1/LMO2, and
TLX3/HOXA transcription factors.
A third cluster included cases that highly expressed CD1
genes. This corresponded with a CD1a-positive immunopheno-
type for most cases of this cluster (p < 0.001; Table 1), which
validated our gene expression data. This cluster also comprised
most TLX1-translocated cases, a genetic entity that was previ-
ously associated with CD1 positivity and cortical developmental
arrest (Ferrando et al., 2002), and thatmay share a similar biology
with the other samples present in this cluster. In the unsuper-
vised cluster analysis, this cluster is characterized by expression
of genes that are involved in cell cycle regulation (CDKN3), G1/S
transition (UHRF1, CDC2), cell cycle progression (TTK, E2F7,
CDC2), DNA replication and chromosome condensation(TOP2A), the spindle-assembly checkpoint (NUSAP1,
MAD2L1, KIF15, KIF11), the G2/M checkpoint (PBK), and genes
whose expression are linked to cell cycle (RRM2, ECT2). Further-
more, differentially expressed genes for this cluster compared to
all other T-ALL cases as identified by t-statistics were enriched
for genes that are strongly associatedwith the cell cycle pathway
and spindle assembly (Table S4), and this cluster strongly ex-
pressed the proliferationmarkerMKI67. This cluster was accord-
ingly denoted as ‘‘proliferative cluster.’’ Most of the cases in this
cluster lacked currently known driving mutations, which may
point toward involvement of not yet identified T-ALL oncogenes.
This was further supported by the fact that most of these
unknown samples clustered as a separate entity (12 cases)
distinct from established T-ALL genetic subgroups, including
the TLX1-rearranged cases in a supervised cluster analysis
(Figure 1C).
The fourth cluster was enriched for immunophenotypic imma-
ture CD4/CD8 double-negative cases (p = 0.008; Table 1), and
was named the ‘‘immature cluster’’ by reference to previous
work (Soulier et al., 2005). Samples in this cluster frequently ex-
pressed myeloid markers CD13 and/or CD33 (p = 0.006), and
were characterized by expression of genes associated with
protein binding, protein dimerization, and TGFBR1-signal trans-
duction. They expressed low levels of genes associated with
cellular proliferation contrary to samples of the proliferative
cluster (Figure 1B). This cluster comprised threeHOXA-activated
cases with an immature immunophenotype unlike other HOXA-
activated cases that usually have amore advanced immunophe-
notype. Other samples in this immature cluster were devoid of
known driving mutations. This cluster may comprise a second
molecular-cytogenetic T-ALL entity for which driving oncogenes
are unknown, and in support of this notion, most of these
samples appeared as a separate subgroup (12 cases) in the
supervised principal component analysis (PCA) based on differ-
entially expressed genes among the known four T-ALL genetic
subgroups (Figure 1C). This immature cluster largely overlaps
with the LYL1-positive cluster as described earlier (Ferrando
et al., 2002) because it expressed the highest LYL1 levels (Table
1). Our immature cluster was highly enriched for ETP T-ALL
cases, as previously described (Coustan-Smith et al., 2009),
because 13 out of 15 immature cases, in contrast to only three
out of 102 remaining cases, were predicted as ETPs by
prediction analysis for microarrays (PAM) using the 62 probe
set profile that defined the ETP group (p < 0.001; data not
shown). In contrast to that study (Coustan-Smith et al., 2009),
the overall survival (OS) for immature cases in our cohort was
not extremely poor (5-year OS = 73% ± 11%) but seemed
equally low to the outcome of TAL/LMO or TLX subgroups
(5-year OS = 65% ± 6%). The proliferative subgroup seemed
to have an improved outcome (5-year OS = 88% ± 8%), albeit
not significant (p = 0.096; Figure S2).
We then searched for candidate genes that participate in
oncogenic chromosomal abnormalities using several methods,
including COPA (Tomlins et al., 2005), SAM (Tusher et al.,
2001), and PAM statistics (Tibshirani et al., 2002). Both COPA
and PAM analyses identified NKX2-1 and MEF2C as character-
istic genes for the proliferative and immature clusters, respec-
tively (Table S5). The NKX2-1 homologous NKX2-2 gene was
also identified by COPA as outlier gene for the proliferativeCancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc. 485
Figure 1. Identification of Two Entities in Pediatric T-ALL that Lack Known Driving Oncogenic Hits
(A) Unsupervised hierarchical cluster analysis by the average linkage method in dChip based on 435 probe sets (Table S3) for RMA-solo (Soulier et al., 2005)
normalizedU133 plus two Affymetrix data from 117 pediatric T-ALL samples and seven normal bonemarrow controls. Cytogenetic rearrangements indicated are:
S, SIL-TAL1; T, TAL1; t, TAL2; O, LMO1; L, LMO2 (includes del(11)(p12p13)); $, TAL2/LMO1; N, SET-NUP214; C, CALM-AF10; M, MYB; A, Inv(7)(p15q34); 1,
TLX1; 3, TLX3; and n, normal bonemarrow controls. The 50th and/or the 25th percentiles of samples with the highest TAL1 or LYL1 expression, positivity for TLX1
and TLX3 expression as measured by RQ-PCR, and expression of the immunophenotypic markers CD13 and/or CD33, CD4 or CD8 are indicated; u, no data
available.
(B) Pearson correlation plot for the patient samples belonging to the four unsupervised TAL/LMO, TLX, proliferative, and immature clusters.
(C) PCA of patients with pediatric T-ALL based upon the top 100 most significant differentially expressed probe sets among major T-ALL subgroups (i.e., TAL1/
LMO2, HOXA, TLX1, and TLX3 [Table S3]). The immature cluster (12 cases) and the proliferative cluster (12 cases) are indicated by green and purple
dots, respectively. Samples repeatedly assigned to the proliferative or immature clusters (i.e., the core samples) in multiple unsupervised analyses on RMA-solo
(A), RMA, or VSN normalized data sets (not shown) or the supervised cluster analysis (C) are visualized by dark-green or purple dots. See also Figure S1 and
Tables S1–S4.
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MEF2Cwere validated by RQ-PCR (Figure 2) for the proliferative
and immature cluster cases, respectively, that lack known onco-
genic rearrangements. These cases form separate clusters in the
supervised analysis (Figure 1C). NKX2-1 or MEF2C was either
absent or expressed at relative low levels in most cases
belonging to other supervised clusters. However, some TLX1-
positive patient samples that are part of the proliferative cluster
in the unsupervised analyses express NKX2-1. Also, the
CALM-AF10-positive HOXA-activated patient sample No. 1509
that highly expresses MEF2C has an immature phenotype and
co-clusters in the immature cluster in unsupervised analyses.486 Cancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc.Molecular-Cytogenetic Identification of NKX2-1
Rearrangements
These data formed the start of detailed molecular-cytogenetic
analyses on the 12 immature cluster and the 12 proliferative
cluster samples that seemed to form two genetic T-ALL entities
(Figure 1C), and for which driving oncogenic hits were unknown.
We used a variety of molecular-cytogenetic techniques including
FISH, array-comparative genomic hybridization (array-CGH),
and Chromosome Conformation Capture on Chip (4C) (Simonis
et al., 2009) to identify potential deletions, amplifications, and
T cell receptor- or BCL11B-driven oncogenic events (Table 2;
Table S6). The 4C method was originally developed to study
Table 1. Clinical and Biological Characteristics of Unsupervised T-ALL Clusters
Cohort TAL/LMO TLX Proliferative Immature p Value
Total (n) 117 53 30 19 15
Clinical
Gender (n)
Male 83 71% 40 75% 20 67% 15 79% 8 53%
Female 34 29% 13 25% 10 33% 4 21% 7 47% 0.306a
Age at diagnosis (years)
Median 7.8 9.3 7.7 5.5 10.1
Range 1.5–17.8 1.6–16.7 3.2–17.8 1.5–16.7 3.1–16.4 0.404b
WBC (10 3 10E9/l)
Median 115.1 156.9 121.9 64.3 87.6
Range 1.8–900 16.1–900 1.8–417 27.2–192 2.3–435 0.001b
Immunophenotype
CD34 (n) 111
Negative 77 69% 37 71% 19 66% 14 93% 7 47%
Positive 34 31% 15 29% 10 34% 1 7% 8 53% 0.046a
CD13/33 (n) 110
Negative 92 84% 47 92% 19 73% 17 94% 9 60%
Positive 18 16% 4 8% 7 27% 1 6% 6 40% 0.006a
CD1 (n) 113
Negative 62 55% 33 65% 14 47% 3 17% 12 86%
Positive 51 45% 18 35% 16 53% 15 83% 2 14% <0.001a
CD4 (n) 115
Negative 42 37% 22 42% 4 13% 3 17% 13 87%
Positive 73 63% 30 58% 26 87% 15 83% 2 13% <0.001a
CD8 (n) 115
Negative 45 39% 14 27% 16 53% 2 11% 13 87%
Positive 70 61% 38 73% 14 47% 16 89% 2 13% <0.001a
CD4/8 (n) 115
Negative 61 53% 26 50% 17 57% 5 28% 13 87%
Positive 54 47% 26 50% 13 43% 13 72% 2 13% 0.008a
CD3 (n) 114
Negative 59 52% 21 40% 19 63% 10 59% 9 60%
Positive 55 48% 31 60% 11 37% 7 41% 6 40% 0.169a
Oncogenes
TAL1 (% expression of GAPDH 3 10E-2)
Median 3.1 13 0.73 1.4 1.14
Range 0.09–1820 0.75–1820 0.088–11 0.17–22 0.10–14 <0.001b
LYL1 (% expression of GAPDH 3 10E-4)
Median 1.7 1.3 3.1 3.5 8.5
Range 0–126 0–32 0–16.6 0.28–15.3 0.96–126 0.001b
a The p values are calculated according to the chi-square test. See also Figure S2.
b The p values are calculated according to the Mann-Whitney U test. See also Figure S2.
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it was recently shown that it robustly identifies chromosomal re-
arrangements, in particular inversions and translocations, even
when they are balanced (Simonis et al., 2009). In the proliferative
cluster, two out of 12 samples were characterized byMYB trans-
locations, a rearrangement considered as a driving oncogenic hit
(Clappier et al., 2007). No furtherMYB translocations were iden-
tified in the remaining ten cases by FISH (Table S6).We identifiedfive rearrangements of NKX2-1 or NKX2-2 genes in seven out of
12 patient samples that, to our knowledge, were not observed
before in human cancer (Table 2, and Figures 3A–3E; Figure S3).
The NKX2-1 gene was inverted to the T cell receptor gene TRA@
in two cases (Nos. 1446 and 9247), inverted to the immunoglob-
ulin heavy-chain gene IGH@ in one case (No. 9919), and translo-
cated to the TRB@ locus (t(7;14)(q34;q13)) in one other case (No.
9989), as identified by 4C analyses (Figure 3A). NKX2-1Cancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc. 487
Figure 2. Validation of Elevated NKX2-1 and MEF2C Levels in Patients from Proliferative and Immature Supervised Clusters
Relative expression levels of (A)NKX2-1 or (B)MEF2C are determined by RQ-PCR.NKX2-1 andMEF2C expression levels are indicated for 11 out of 12 immature
cluster patient samples (green) and 12 proliferative cluster samples (purple) according to the supervised analysis (Figure 1C) compared to cases of other T-ALL
molecular-cytogenetic subgroups. The SEMs are shown. See also Table S5.
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NKX2-1 and MEF2C as Potential Oncogenes in T-ALLrearrangements in these patients were validated by FISH (Fig-
ure 3B). The der(7) chromosomal breakpoint for this t(7;14)
(q34;q13) in patient No. 9919 was cloned (Figure 3C). A fifth
patient (No. 2641) had a NKX2-1 rearrangement based on
FISH results (Table 2; data not shown), whereas a sixth patient
(No. 2702) had an amplification at 14q13 based on array-CGH
(Figure 3D), presumable due to aNKX2-1 duplication or an inser-
tion into another chromosome (data not shown). These patients
highly expressed NKX2-1 protein levels (Figure 3F, representa-
tive cases are shown). A seventh case (No. 10138) had a translo-
cation between the homologous NKX2-2 gene and the TRD@
locus, for which both reciprocal breakpoint regions were cloned
(Figure 3E). This patient highly expressed NKX2-2 protein levels
(data not shown). For the TLX1-rearranged cases that co-cluster
with these NKX2-1/NKX2-2 rearranged cases in unsupervised
cluster analysis that also expressed NKX2-1 (Figure 2A), we
did not find evidence for NKX2-1 rearrangements by FISH
(data not shown). This indicates that TLX1 and NKX2-1/
NKX2-2 oncogenes may exert identical or closely related patho-
genic mechanisms.
Molecular-Cytogenetic Identification ofMEF2C
and MEF2C-Activating Rearrangements
We subsequently investigated the 12 immature cluster cases
lacking known driving oncogenic hits, and identified chromo-
somal abnormalities that converge on the activation of the
MEF2C gene in at least five cases. Two cases had chromosomal
copy number loss of the 5q14-qter chromosomal arm with
breakpoint in a 0.5–2Mb proximity telomeric ofMEF2C. A similar
deletion was also identified in T-ALL cell line LOUCY (Figure 4A).
These 5q14-qter deletions were not identified in 90 other T-ALL
cases as included in our profiling study for which array-CGHdata
were available (Figure S4A). For patient No. 1964, this 5q14-qter
deletion was part of an unbalanced chromosomal translocation
between chromosomal bands 5q14 and 4q27 fusing the telo-
meric MEF2C region to the telomeric region 0.6 Mb distal of
the PITX2 gene on chromosome 4 (Figure 4B). In contrast to
other genes in the 5q14 region, MEF2C is highly upregulated in488 Cancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc.both patients indicating that MEF2C represents the target of
these 5q rearrangements (Figures S4B ad S4C).
A NKX2-5/BCL11B translocation was identified by FISH in a
third case (Figure 4C), and this case highly expressed NKX2-5.
This rare translocation has been reported in T-ALL before (Nagel
et al., 2003). Knockdown of NKX2-5 levels by siRNAmolecules in
the NKX2-5 translocation-positive cell line PEER lowered
MEF2C levels (Figures 5A–5C), indicating that NKX2-5 controls
MEF2C. Chromatin immunoprecipitation (ChIP) experiments
confirmed that NKX2-5 directly binds in the promoter region of
MEF2C (Figure 5D).
A fourth case harbored aBCL11B translocation to SPI1, which
encodes for PU.1 (Figure 4D). This patient uniquely expressed
SPI1 compared to the other T-ALL cases in this study (Figure 4E).
PU.1 was recently identified as important regulator for MEF2C
expression in normal lymphoid development (Stehling-Sun
et al., 2009), and this patient with T-ALL highly expressed
MEF2C (Figure 2B and Table 2).
A fifth case (No. 1524) harbored a t(8;12)(q13;p13) as identified
by FISH (Figures S4D and S4E), resulting in reciprocal ETV6-
NCOA2 fusion products, and both reciprocal breakpoints were
cloned for this patient (Figure 4F). Similar fusions were recently
identified in biphenotypic T-ALL (Strehl et al., 2008). NCOA2 is
a known coregulator of MEF2C (Chen et al., 2000), and MEF2C
was found consistently upregulated in selected ETV6–NCOA2
rearranged cases (Figure 4G).
A sixth immature casewith highMEF2C levels had a karyotypic
t(2;21) that involved the RUNX1/AML1 gene (Figure S4F). For
this patient we cloned reciprocal in-frame RUNX1-AFF3 and
AFF3-RUNX1 fusion products as consequence of this transloca-
tion (Figure 4H). How RUNX1 fusion products could upregulate
MEF2C expression remains to be determined.
To investigate whether MEF2C could indeed regulate the
expression of various genes from the immature signature,
MEF2C stable-transfected clones and mock-transfected
controls were generated for the cell line Jurkat (Figure 5E) that
does not have an immature signature (data not shown). As
shown in Figure 5F, the MEF2C-transfected Jurkat clone 2B3,
Table 2. Identified Rearrangements in Patient Samples of the Proliferative and Immature Clusters
Proliferative Cluster
Patient Number NKX2-1 Expressiona Aberration Partner Gene 1 Partner Gene 2 Methods
9919b + inv(14)(q13q32.33) IGH@ NKX2-1 FISH, 4C
9247b + inv(14)(q11.2q13) TRA@ NKX2-1 FISH, 4C
10138b +c t(14;20)(q11;p11) TRD@ NKX2-2 FISH, LM-PCR
914 + t(6;7)(q22-23;q34) TRB@ MYB FISH
2113 + – – – –
2641 + Rearrangement ? NKX2-1 FISH
9989b + t(7;14)(q34;q13) TRB@ NKX2-1 FISH, 4C
2702b + dup(14)(q13.3q13.3) or ins(?)(?q13.3) ? NKX2-1 Array-CGH, FISH
1446b + inv(14)(q11.2q13) TRA@ NKX2-1 FISH, 4C
9105 + t(6;7)(q22-23;q34) TRB@ MYB FISH
9696 – – – –
9827 – – – –
Immature Cluster
Patient Number MEF2C Expressiona Aberration Partner Gene 1 Partner Gene 2 Methods
10030d + – – – –
2703 + – – – –
2130 – – – –
2252 + t(11;14)(p11.2;q32.2) BCL11B SPI.1 FISH, 4C
167d + – – – –
321d + – – – –
491d + del(5)(q14) – MEF2C FISH, array-CGH
572d + t(2;21)(q11.2-12;q22.3) RUNX1 AFF3 Karyotype, 30-RACE
1524d + t(8;12)(q13;p13) ETV6 NCOA2 RT-PCR, FISH
1964d + der(5)t(4;5)(q26;q14) 4q26 MEF2C 4C, array-CGH
9577 + t(5;14)(q34;q32.2) BCL11B NKX2-5 FISH
9226 ± – – – –
Cell Lines
LOUCY + t(5;14)(q34;q32.2) BCL11B NKX2-5 (Przybylski et al., 2006)
PEER + del(5)(q14) – MEF2C (Nagel et al., 2008)
aNKX2-1 or MEF2C expression based on expression array and/or RQ-PCR results.
bCore proliferative cases repeatedly assigned in unsupervised and supervised analyses to the immature or proliferative clusters, respectively. See also
Table S6 and Figure S6.
c Sample No. 10138 expresses the NKX2-1 homologous NKX2-2 gene.
dCore immature cases repeatedly assigned in unsupervised and supervised analyses to the immature or proliferative clusters, respectively. See also
Table S6 and Figure S6.
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NKX2-1 and MEF2C as Potential Oncogenes in T-ALLbut not the mock-transfected control 3G4, highly activates five
out of six selected immature signature genes (PSCD4, HHEX,
FAM46A, LMO2, and LYL1), indicating that MEF2Cmay function
as a transcriptional regulator for many genes that are highly
expressed in immature T-ALL cases. For the reciprocal setting
in cell line PEER, knockdown of NKX2-5 using siRNA molecules
that reduced MEF2C expression (Figures 5A–5C) also led to
reduced levels of LMO2, LYL1, and HHEX (Figure 5G). Onco-
genic rearrangements of LMO2, LYL1, and the LYL1 homolo-
gous TAL1 gene are exclusively found in the TAL/LMO subgroup
but have never been observed in immature T-ALL cases (this
work; Ferrando et al., 2002). Activation of LMO2 and LYL1
through MEF2C may be crucial to prime early-committed
T cells for leukemogenesis. By using ChIP we demonstrated
that MEF2C directly binds to the promoter of HHEX as well asto the distal and proximal promoters of LMO2 in the immature
cell line LOUCY. This could also be demonstrated for diagnostic
leukemic cells of three patients that belong to the immature
cluster (Nos. 491, 321, and 167; data not shown), but not in
the control cell line Jurkat (Figure 5H). The MN1 gene, which is
targeted by chromosomal alterations in inv(16) M4EO AML
subtype (Buijs et al., 2000; Grosveld, 2007), was also identified
as a highly activated gene for the immature cluster (Table S5).
As for HHEX, we did not find evidence for chromosomal
rearrangements of MN1 by FISH in immature T-ALL cases
(Table S6).
Oncogenic Activity of NKX2-1 and MEF2C
To substantiate potential oncogenic activity for NKX2-1 and
MEF2C, we tested whether both genes had transformingCancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc. 489
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Figure 4. MEF2C-Activating Rearrangements for Immature Cluster Samples
(A) Array-CGH results for chromosomes 4 and/or 5 for patient Nos. 491 and 1964. Blue and red tracings represent two independent, dye-swopped experiments.
Positions of MEF2C and PITX2 have been indicated.
(B) Visualization of an unbalanced chromosomal translocation t(4;5)(q26;q14) for patient No. 1964 by 4C analysis. The MEF2C VP is indicated by an arrow.
Running median of probe set intensities for chromosomes 5 and 4 are indicated in red and blue, respectively.
(C) Validation of a chromosomal translocation between NKX2-5 and BCL11B in patient No. 9577 by FISH. Schematic positions of FISH probes are shown.
(D) Identification of the t(11;14)(p11.2;q32.2) chromosomal translocation between SPI1 and BCL11B in patient No. 2252 by 4C. The VP is positioned 0.6 Mb
upstream of BCL11B, as indicated by an arrow.
(E) Ectopic SPI1 expression in patient No. 2252 compared to 116 additional T-ALL patient samples. Raw fluorescent intensities of probe set 205312_at are shown.
(F) Cloned fusion areas for reciprocal ETV6-NCOA2 and NCOA2-ETV6 fusion transcripts in patient No. 1524.
(G) RelativeMEF2C expression by RQ-PCR in three selected ETV6-NCOA2 rearranged T-ALL patients (Nos. 1–3). Cell lines LOUCY and PF382 are positive and
negative controls for MEF2C expression, respectively.
(H) Cloned fusion areas for reciprocal RUNX1-AFF3 and AFF3-RUNX1 fusion transcripts for patient No. 572. See also Figure S4.
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NKX2-1 and MEF2C as Potential Oncogenes in T-ALLcapacity by using cellular transformation assays in NIH 3T3 (Fig-
ure 6A) or BJ-EHT cells (Figure 6B). Transfecting NKX2-1 or
MEF2C expression constructs into the cells was insufficient to
drive cellular transformation. We then tested cellular transforma-
tion of MEF2C and NKX2-1 when combined with RAS or MYC,
two oncogenes that are frequently activated in T-ALL through
RAS or NOTCH1-activating mutations (Kawamura et al., 1999;
Palomero et al., 2006; Weng et al., 2006). NKX2-1 and MEF2C
were both able to synergize with RAS or MYC genes in driving
cellular transformation (Figures 6A and 6B).Figure 3. NKX2-1 and NKX2-2 Rearrangements in Proliferative Cluster
(A) 4C results obtained fromNKX2-1 or TRB@ VPs. Positions of TRA@,NKX2-1, an
shown in gray. Higher magnifications of the reciprocal breakpoint regions are giv
(B) Validation of NKX2-1 rearrangements by FISH. Schematic positions of FISH
(C) Schematic representation of the der(7) breakpoint region and breakpoint seq
(D) Visualization of a single-copy NKX2-1 amplification (green box) in patient No
(E) Schematic representation of t(14;20)(q11;p11) breakpoint regions and cloned
(F) NKX2-1 protein expression in representative proliferative cluster and immature
control.We then further tested the importance of MEF2C for T cell
pathogenesis for which we had a cell line model available. In
normal human T cell development subsets,MEF2C is exclusively
expressed at the pre-DN1 and DN1 stages, after which it is
downregulated (Figure S5). We knocked down MEF2C expres-
sion in T-ALL cell line LOUCY using siRNA molecules. MEF2C
knockdown induced cellular differentiation as LOUCY cells
became positive for membrane CD3 and TCRgd expression
(Figures 6C–6E). This indicates that MEF2C can block T cell
differentiation at a very immature stage.Patient Samples
d IGH@ loci are shown by gray vertical bars. 4C results for a normal control are
en in Figure S3.
probes are shown.
uence of the unbalanced t(7;14)(q34;q13) for patient No. 9989.
. 2702 as identified by array-CGH.
breakpoint sequences for patient No. 10138 with the NKX2-2 rearrangement.
cluster patient samples as shown by western blot. Actin was used as loading
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Figure 5. NKX2-5 Controls MEF2C Expression
(A) RQ-PCR results ofNKX2-5mRNA expression levels or (B) NKX2-5 protein levels in cell line PEER at indicated time points following electroporation with siRNAs
directed against NKX2-5 (black bars) relative to control siRNA-treated cells (gray bars). For western blot analysis, actin was used as a loading control.
(C) RQ-PCR results ofMEF2CmRNA expression levels at indicated time points following electroporation with anti-NKX2-5 siRNAmolecules (black bars) relative
to controls (gray bars).
(D) Enrichment of MEF2C promoter sequences in NKX2-5 ChIP analysis in the NKX2-5 translocated cell line PEER, but not in negative control lines LOUCY or
DND41.
(E) Ectopic MEF2C expression in the MEF2C stably transfected Jurkat clone 2B3, as shown by western blot analysis. The mock-transfected Jurkat clone 3G4
served as negative control.
(F) RQ-PCR results for MEF2C-positive Jurkat clone 2B3 clone or themock-transfected control (3G4) forMEF2C and random selected immature signature genes
that are relatively downregulated (TUSC3, CHRNA3, ENO2) or upregulated (PSCD4 (CYTH4), PDK1, HHEX, FAM46A, LYL1, LMO2) in immature T-ALL cases
compared to other cluster samples.
(G) Relative expression results for HHEX, LYL1, and LMO2 in the cell line PEER 72 hr after electroporation with siRNAs directed against NKX2-5 (black bars)
relative to control siRNA-treated PEER cells (gray bars).
(H) Enrichment of HHEX promoter and the distal and proximal LMO2 promoters upon MEF2C ChIP analysis in the immature cell line LOUCY, but not in the
negative control line Jurkat. For all panels the SDs are shown. Significant differences (p < 0.05) in relative expression levels are indicated by an asterisk (*).
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in Independent T-ALL Cohorts
We then confirmed our T-ALL clustering (Figures 1A and 1C) and
molecular-cytogenetic findings (Table 2) in two independent vali-
dation cohorts, i.e., a French data set comprising 107 pediatric
and adult T-ALL cases (Clappier et al., 2007; Soulier et al.,
2005), and a second Rotterdam cohort comprising 108 pediatric
and adult T-ALL cases. Upon testing the comparability of the
initial Rotterdam cohort and the French data set (Figure S6A),
the proliferative and immature clusters could be reproduced in
a combined unsupervised cluster analysis (Figure S6B). Based
on the unsupervised clustering of our initial Rotterdam cohort,
PAM statistics predicted various proliferative cluster cases as
well as immature cluster cases in the Rotterdam validation
cohort (data not shown). A total of 26 proliferative cluster cases
were identified, of which various samples highly expressed
NKX2-1 (Figure S6C). NKX2-1 translocations/inversions could
be demonstrated using FISH in three cases (Figures S6G–S6I).492 Cancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc.Eight out of ten TLX1-rearranged cases were part of the prolifer-
ative cluster as well (Figure S6D; data not shown), further sup-
porting the notion that NKX2-1 and TLX1 oncogenic rearrange-
ments may share common pathogenic mechanisms. Again,
some of these TLX1-rearranged cases also expressed NKX2-1
at low levels (Figure S6C), whereas none of these samples had
NKX2-1 rearrangements. We also validated highMEF2C expres-
sion for the 24 cases that were assigned to the immature cluster
by PAM analysis (Figure S6E), and these samples expressed the
highest levels of its downstream target LYL1 (Figure S6F).
DISCUSSION
In this study we have identified NKX2-1, its related family
member NKX2-2, and MEF2C as potential oncogenes for
T-ALL. Supervised cluster analyses based on genes uniquely
associated with the known genetic TAL/LMO, TLX3, TLX1, and
HOXA subgroups revealed that samples with high expression
Figure 6. Cellular Transformation by MEF2C and NKX2-1
Cellular transformation of (A) NIH 3T3 or (B) BJ-EHT cells upon transfection ofMEF2C, NKX2-1,MYC, and/or RAS expression vectors as indicated. Significance
levels for colony number differences between indicated expression construct combinations relative to the empty vector control are indicated (*p % 0.05,
**p% 0.01, ***p% 0.001).
(C) MEF2C expression knockdown as measured by RQ-PCR for the MEF2C-positive cell line LOUCY at indicated time points following electroporation with
MEF2C-specific siRNA molecules (black bars) relative to control siRNA-treated cells (gray bars).
(D) Downregulation of MEF2C protein following treatment with MEF2C-specific siRNA molecules as validated by western blot. Based on the protein size, the
predominant a1b (47 kDa) and the a1bg (51.2 kDa) MEF2C isoform (Zhu and Gulick, 2004) are indicated.
(E) Increase of mCD3 (p = 0.0032) and TCRgd (p = 0.023) expression as demonstrated by FACS analysis in LOUCY cells, 96 hr following treatment withMEF2C-
specific siRNA molecules. A representative example from three independent experiments is shown. For all panels the SEMs are shown. See also Figure S5.
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NKX2-1 and MEF2C as Potential Oncogenes in T-ALLof NKX2-1/NKX2-2 or MEF2C characterize two T-ALL clusters
for which no driving oncogenic hits have been identified so far.
Both clusters represent about 20% of all T-ALL cases.
Variant rearrangements for NKX2-1 and NKX2-2 to T cell
receptor genes (TRAD@, TRB@) were identified, and one case
had an inversion to the IGH@ locus. The IgH enhancer seems
functional in this patient with T-ALL, and IgH enhancer (Em)
driven oncogene expression in a T cell context has been
described before, both for human T-ALL (Nguyen-Khac et al.,
2010) as well as in transgenic mouse models (Katsumata et al.,
1992; Strasser et al., 1991). This patient did not express B cell
markers, therefore excluding it as a biphenotypic leukemia.
NKX2-1 was able to transform NIH 3T3 and BJ-EHT cells in
synergism with RAS or MYC, two genes that become activated
through RAS or NOTCH1-activating mutations in approximately
15% and 60% of T-ALL cases, respectively (Kawamura et al.,
1999; Palomero et al., 2006; Weng et al., 2006). Therefore, our
data strongly support thatNKX2-1/NKX2-2may represent onco-
genes in T-ALL. NKX2-1 is not expressed during normal T celldevelopment based on expression data by microarray for flow-
sorted thymic subsets (Dik et al., 2005; Soulier et al., 2005).
NKX2-1 andNKX2-2 have been associated with other types of
cancer before: NKX2-1 is amplified in human lung cancer (Weir
et al., 2007); and NKX2-2 is a target of the EWS/FLI fusion
product in Ewing’s sarcoma (Smith et al., 2006). NKX2-1 and
NKX2-2 are 59% identical for the homeodomain region, indi-
cating that both proteins may exert identical oncogenic roles in
T-ALL. This is further supported by the fact that rearrangements
for both genes were identified in samples that tightly cluster
together in unsupervised and supervised analyses. NK-like
homeobox transcription factors play important roles in T-ALL
because NKX2-5 was previously identified as part of an onco-
genic rearrangement in T-ALL (Nagel et al., 2003). The NK-like
homeobox transcription factor NKX3-1 has been found to be
highly activated in TAL1-rearranged cases (Soulier et al.,
2005), as a direct TAL1 target gene (Kusy et al., 2010). The home-
odomains of NKX2-5 and NKX3-1 are only distantly related (37%
identity) and only 48% and 47% identical to the homeodomain ofCancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc. 493
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NKX2-1 and MEF2C as Potential Oncogenes in T-ALLNKX2-1, respectively. This may explain why NKX2-5, NKX3-1,
and NKX2-1/NKX2-2 are associated with different T-ALL
subgroups: ectopic NKX3-1 expression in the TAL/LMO
subgroup (Soulier et al., 2005); NKX2-1/NKX2-2 rearrangements
with the proliferative T-ALL cluster (this study); and NKX2-5
translocations with immature T cell development (this study)
that activates MEF2C (this study; Nagel et al., 2008).
In unsupervised analyses, NKX2-1/NKX2-2 rearranged
cases cluster together with TLX1-rearranged cases to form the
proliferative cluster. This indicates that NKX2-1/NKX2-2 and
TLX1-rearranged T-ALLs are biologically related. This is further
supported by the fact that NKX2-1 and TLX1-rearranged cases
share a similar immunophenotypic makeup consistent with
cortical arrest as well by the fact that various TLX1-rearranged
cases express NKX2-1 in the absence of NKX2-1 rearrange-
ments, albeit at low levels. One of the explanations may be
that TLX1 controls NKX2-1 expression. In addition several other
cases that are part of the proliferative cluster lack TLX1,NKX2-1,
or NKX2-2 rearrangements, indicating that an additional onco-
genic rearrangement awaits identification for this cluster.
The second cluster had a very immature immunophenotype,
with most cases expressing CD34 and frequently coexpressing
the CD13 and/or CD33 myeloid markers. We identified various
rearrangements that directly or indirectly activate MEF2C.
MEF2C is a member of the MADS-box transcription factor family
that includes the fourMEF2A-D genes that are important regula-
tors of skeletal muscle development (Grounds, 1991). Immature
T-ALL subgroups have been identified before (Coustan-Smith
et al., 2009; Ferrando et al., 2002; Soulier et al., 2005), and our
immature cluster cases could also be predicted based on an
ETP expression signature (Coustan-Smith et al., 2009). We
now conclude thatMEF2C is the driving oncogene for immature
(ETP) T-ALL cases. Our immature cases also have the highest
LYL1 expression and highly express LMO2 (Ferrando et al.,
2002; this study). LYL1 and LMO2 are members of the basic-
helix-loop-helix (bHLH) family and the LIM-domain only family,
respectively. Apart from LYL1 and LMO2, the immature cases
also highly express the homeobox gene HHEX. We have now
shown that HHEX, LYL1, and LMO2 are being regulated by
MEF2C, and it was proven that MEF2C directly binds in the
promoter regions of at least HHEX and LMO2. This may support
a pathogenic role for established oncogenes such as LYL1 and
LMO2 in MEF2C-deregulated early-committed T cells. To what
extend LMO2 and/or LYL1 as MEF2C targets will be sufficient
to drive a leukemogenic program in these early-committed
T cells is presently unclear. To our knowledge, oncogenic rear-
rangements of LMO2 and LYL1 have not been observed in
immature T-ALL (Ferrando et al., 2002; this work) but are exclu-
sive for the TAL/LMO subgroup that also includes rearrange-
ments of the LYL1-homolog TAL1. Therefore, MEF2C may elicit
a more comprehensive transcriptional program characteristic for
ETP T-ALLs than aberrant expression of LMO2 or LYL1 alone.
MEF2C is a key regulator for lymphoid development that is
activated by PU.1 (Stehling-Sun et al., 2009). In B cell develop-
ment, MEF2C is activated by calcineurin following BCR trig-
gering and warrants for cell viability and proliferation (Wilker
et al., 2008). MEF2C has been implicated in human oncogenesis:
in myeloid leukemias of MLL-AF9 transgenic mice, Mef2c has
been identified as a HoxA9 target gene that regulates self-494 Cancer Cell 19, 484–497, April 12, 2011 ª2011 Elsevier Inc.renewal of leukemic stem cells (Krivtsov et al., 2006). MEF2C is
also highly expressed in human MLL-rearranged AML that is
characterized by upregulation of HOXA genes, including
HOXA9 (Schwieger et al., 2009). Mef2c is further identified as
potential oncogene in insertional mutagenesis studies (Du
et al., 2005; Schwieger et al., 2009) and can provoke myeloid
leukemias (Schwieger et al., 2009). Also, the related family
member MEF2D is involved in the MEF2D-DAZAP1 fusion that
has been identified in ALL (Prima and Hunger, 2007).
Many oncogenic hits as identified in this study involve early
hematopoietic transcription factors, including NKX2-5, PU.1,
and presumably RUNX1. These factors are important for normal
T cell development (Rothenberg, 2007). All these factors
converge on MEF2C in immature T-ALL, and it is tempting to
speculate that MEF2C is a central regulator for normal early
T cell development. MEF2C may need to become downregu-
lated to facilitate maturation beyond this immature stage, and
we indeed demonstrated that knockdown of MEF2C expression
in T-ALL cell line LOUCY provoked differentiation. In support of
these notions, MEF2C is expressed in normal human thymocyte
pre-DN1 and DN1 subsets, but expression is dramatically
decreased beyond the DN2 stage (Figure S5). A similar downre-
gulation of MEF2C expression could be validated from gene
expression data for equivalent flow-sorted thymic subsets, as
published (Dik et al., 2005; data not shown). MEF2C may repre-
sent the central oncogene for immature T-ALL cases that seems
to provide a T cell differentiation block at the immature stage, as
demonstrated in this article. This was further supported by our
transformation assay results in which MEF2C transformed NIH
3T3 and BJ-EHT cells in combination with RAS or MYC. We
also observed that several genes from the TGFBR1 pathway
were upregulated, including TGFBR1, ZEB2, SMAD7, SMURF2,
and RUNX3, or downregulated (SMAD1). Because both activa-
tors (TGFBR1) and inhibitors (like SMURF2, SMAD7) are overex-
pressed while the activator SMAD1 is underexpressed, it is diffi-
cult to anticipate the functional consequences of this pathway
for the immature T-ALL cases.
In conclusionweusedastrategy integratingmoleculargenetics
with large-scale expressionprofilingand identified twooncogenic
subgroups and eight genomic rearrangements that, to our knowl-
edge, have not been identified before in human T-ALL or other
cancer types. We have shown that these proliferative and imma-
ture subtypes reflect different biological entities: the proliferative
cluster strongly expresses proliferation genes and is associated
with aberrations and ectopic expression of NKX2-1 or NKX2-2,
and expression of CD1. In contrast the immature cluster was
characterized by immature T cell development, activation of
genes involved in protein binding and dimerization, expression
of components of the TGFBR1 pathway, and high expression of
the MADS transcription factor MEF2C due to abnormalities of
MEF2C, transcription factors that regulate MEF2C, or MEF2C-
associating cofactors. We conclude that NKX2-1, NKX2-2, and
MEF2C define oncogenic pathways in T-ALL.EXPERIMENTAL PROCEDURES
Patient Samples
Viably frozen diagnostic bone marrow or peripheral blood samples from
117 patients with pediatric T-ALL and corresponding clinical and
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NKX2-1 and MEF2C as Potential Oncogenes in T-ALLimmunophenotypic data were provided by the German Co-operative study
group for childhood Acute Lymphoblastic Leukemia (COALL) and the Dutch
Childhood Oncology Group (DCOG). The patients’ parents or their legal guard-
ians provided informed consent to use leftover material for research purposes
according to the Declaration of Helsinki. This study was approved by the Insti-
tutional Review Board of the Erasmus MC, Rotterdam. Leukemic cells were
isolated and enriched from these samples as previously described (Van Vlier-
berghe et al., 2006). All resulting samples containedR90% leukemic cells, as
determined morphologically by May-Gru¨nwald-Giemsa-stained cytospins
(Merck, Darmstadt, Germany). Patients were assigned to specific molecular-
cytogenetic T-ALL subgroups based on FISH results for TAL1, TAL2, LMO1,
LMO2, TLX1, TLX3, CALM-AF10, SET-NUP214, MLL, MYB, or Inv(7)
(p15;q34)), and positivity by RT-PCR for SIL-TAL1, TLX1, TLX3, CALM-
AF10, or SET-NUP214 as described before (van Grotel et al., 2006; Van Vlier-
berghe et al., 2006, 2008b).
4C
4C was performed as described before (Simonis et al., 2006). Briefly, DNA
and protein in approximately 10 million viable cells were crosslinked in a 2%
formaldehyde solution to conserve the physical proximity of DNA regions.
Cells were lysed, and DNA was digested with HindIII. After dilution of DNA,
restriction fragments were ligated. This way, DNA fragments that are physically
near each other in the viable cell can be ligated. The sample was subsequently
de-crosslinked by an overnight incubation at 65C. DNA was purified and
digested with the frequent cutter DpnII. Samples were diluted and ligated to
allow circularization of individual restriction fragments. Following linearization
with ScaI (located between both inverse PCRprimers), DNA sequences ligated
to the fragment of interest were amplified by inverse PCR, labeled, and hybrid-
ized on a microarray (Nimblegen, Madison, WI, USA) containing probes that
roughly represent individual HindIII fragments in the genome. Raw fluores-
cence intensities are visualized as the running median per 30 neighboring
probes, each representing a HindIII restriction fragment. The viewpoint (VP)
is the HindIII restriction fragment where 4C PCR primers are located. Data
are visualized with SignalMap software (Nimblegen) (NCBI, Build 36). Inverse
PCR primer sets developed for NKX2-1, BCL11B, and MEF2C are listed in
the Supplemental Experimental Procedures.
Gene Expression Microarray, Data Extraction, and Normalization
Integrity of patient samples total RNA was checked using the Agilent 2100
Bioanalyzer (Santa Clara, CA, USA). Copy DNA and ccRNA syntheses from
total RNA, hybridization to Humane Genome U133 plus2.0 oligonucleotide
microarrays (Affymetrix, Santa Clara, CA, USA), and washing steps were
performed according to the manufacturers’ protocol. Probe set intensities
were extracted from CEL files in the statistical data analysis environment R,
version 2.8.0 (Bioconductor Affy package). All arrays had a 30–50 GAPDH ratio
lower than 3-fold. Probe intensities were normalized in R using RMA-solo,
RMA (Irizarry et al., 2003), or VSN (Huber et al., 2002) methods.
Biostatistical Analyses
Biostatistical analyses have been described in detail in the Supplemental
Experimental Procedures. Briefly, unsupervised cluster analyses were per-
formed in dChip (Li and Wong, 2001). Identification of differentially expressed
genes with FDR control was done by various methods including Wilcoxon
statistics (‘‘Multtest’’ in R), SAM statistics (Tusher et al., 2001) (BRB tools,
version 3.7, R. Simon & A.P. Lam), and COPA statistics (Tomlins et al., 2005)
for outlier analysis using a R routine. Prediction of identified subtypes was
done using various algorithms embedded in BRB tools including Diagonal
Linear Discriminant Analysis, 1-nearest neighbor, 3-nearest neighbor, and
nearest centroid, as well as tested by PAM (Tibshirani et al., 2002). PCA
based on the top100 most significant differentially expressed genes for the
major T-ALL subgroups (i.e., the supervised analysis) was performed using
GeneMath XT 1.6.1. software (Applied Maths, Inc., Austin, TX, USA). To vali-
date findings from the Rotterdam data set, this data set was combined with
the French (Paris) Affymetrix U133A data set (Soulier et al., 2005). Data for
overlapping probe sets were extracted from both data sets, RMA-solo normal-
ized, and corrected for batch effects using the CombatMethod (Johnson et al.,
2007). Profiles for similar T-ALL subgroups in both data sets were tested for
comparability by using various methods, including the OrderedList methodusing the Bioconductor package ‘‘OrderedList’’ in R (Lottaz et al., 2006) as
well as the subclass method (Hoshida et al., 2007). Additional methods and
materials are described in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
Rotterdam and French microarray data sets are available at http://www.ncbi.
nlm.nih.gov/geo/ and the EBI database at http://www.ebi.ac.uk/arrayexpress
under accession numbers GSE26713 and E-MEXP-313, respectively.
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